|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, it has been shown that PCOS patients with extremely high anti-Mullerian hormone (AMH) level are more likely to experience OHSS during IVF, compared to PCOS patients with lower AMH level.
|
31563697 |
2020 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations observed between AMH and cardio-metabolic indices are largely explained by BMI in women with and without PCOS.
|
31586179 |
2020 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicate that AMH had no effect on the development of COS and PCOS, while KISS-1 was found to affect the development of COS in rats.
|
31782699 |
2020 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Girls with premature adrenarche, especially those from mothers with a history of PCOS, could have a higher risk of developing PCOS later in life because they have increased serum AMH.
|
30529136 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Women with PCOS had higher AMH levels during pregnancy compared with controls, but high AMH was not associated with increased risk of adverse pregnancy outcomes or birthweight.
|
31036431 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Basal Anti Mullerian hormone levels and endometrial thickness at midcycle can predict the outcome after clomiphene citrate stimulation in anovulatory women with PCOS, a retrospective study.
|
31696366 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This meta-analysis showed significantly increased KISS-1 level in PCOS, and its association with AMH reflects its role in reproductive physiology.
|
31515170 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
A micronutrient supplementation that includes omega-3 fatty acids, folic acid, selenium, vitamin E, catechin, glycyrrhizin, and co-enzyme Q10, given for a minimum of 3 months, is beneficial for women with PCOS in terms of PCOS-specific parameters (LH:FSH ratio, serum testosterone and serum AMH).
|
31101977 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum concentrations of BMP15 and GDF9 were analyzed in women relative to age, anti-Müllerian hormone, number of oocytes retrieved, and polycystic ovary syndrome (PCOS) after superovulation for in vitro fertilization.
|
31211369 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the AMH assay can become an indirect marker of the remaining female fertile years in some cases such as those women that are at risk for premature ovarian failure or in those suffering from polycystic ovary syndrome.
|
31398713 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AMH levels were not correlated with 25(OH)D levels in the NOR or the PCOS group (r = - 0.112, p = 0.008; r = 0.027, p = 0.836).
|
31303660 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis.
|
31160167 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When comparing the indications for IVF/ICSI, we observed a significant decrease in AMH serum levels after repetitive oocyte retrievals only in women with PCOS, while the decrease in AMH was not significant in patients with tubal factor, endometriosis, male factor and unexplained infertility.
|
30790103 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> PCO: polycystic ovaries; HCG: human chorionic gonadotropin; GV: germinal vesicle; MII: metaphase II; IVM: <i>in vitro</i> maturation; IVF: <i>in vitro</i> fertilization; IVC: <i>in vitro</i> culture: MVC: microvibration culture; SC: static culture; ICSI: intracytoplasmic sperm injection; IVM/F-ET: IVM and fertilization-embryo transfer; AMH: anti-Mullerian hormone; OHSS: ovarian hyperstimulation syndrome.
|
31002532 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were no significant differences between values of AMH and LH/FSH ratio in PCOS diagnosis, as the difference between the two AUCs was 0.013, 95% CI: -0.024 to 0.028 and P = 0.897.
|
30636332 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serum AMH level had a significant positive effect on the likelihood of AFC changes in patients with PCOS and control-group women.
|
30535164 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Firth penalized logistic regression model with backward selection identified four independent predictors of PCOS namely free androgen index [β 0.30 (0.12), P = 0.008], 17-OHP [β = 0.20 (0.01), P = 0.026], anti-mullerian hormone [AMH; β = 0.04 (0.01) P < 0.0001] and waist circumference [β = 0.08 (0.02), P < 0.0001].
|
30339716 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, we found that the other genotypes for non-obese PCOS group, AG/GG for rs12970134 and CT/TT for rs17782313, are associated with hirsutism, loss of hair, hyperandrogenism and anti-Müllerian hormone in PCOS.
|
31429705 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of electroacupuncture in regulating the imbalance of AMH and FSH to improve follicle development and hyperandrogenism in PCOS rats.
|
30851546 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The differential dose-related effect of AMH on gene expression and SMAD signalling was investigated in human granulosa-luteal cells (hGLC) from women with normal ovaries, with polycystic ovarian morphology (PCOM) and with PCOS.
|
31735954 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anti-Müllerian hormone (AMH) levels in PCOS-d were significantly increased compared with OB-g, who tended to have lower AMH levels than NW-g (PCOS-d vs OB-g, P < 0.0001; PCOS-d vs NW-g, P = 0.10).
|
30844044 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, AMH participates in the diagnosis of certain diseases such as granulosa cell tumors or Polycystic Ovary Syndrome (PCOS).
|
30352309 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anti-Müllerian hormone level is associated with vitamin D receptor polymorphisms in women with polycystic ovary syndrome.
|
31089932 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To provide further insight into the mechanism of follicle arrest in PCOS, we profiled (i) gonadotropin receptors; (ii) characteristics of aberrant steroidogenesis; and (iii) expression of anti-Müllerian hormone (AMH) and its receptor in granulosa cells (GCs) from unstimulated, human small antral follicles (hSAFs) and from granulosa lutein cells (GLCs).
|
31276164 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The IVM and the COS groups differed significantly (P < 0.001) for maternal circulating AMH levels and PCOS phenotype distribution, with more of the PCOS phenotype A in the IVM group.
|
31347678 |
2019 |